Mpox primer for clinicians: what makes the difference in 2024?

By sjmartinez • January 16, 2025

Abdel-Rahman SM, Bayıcı BZ, Keske Ş, Kuşkucu M, Özsürekçi Y, Rimoin AW, Rodriguez-Morales AJ, Ergönül Ö. Mpox primer for clinicians: what makes the difference in 2024? Curr Opin Infect Dis. 2025 Jan 16. doi: 10.1097/QCO.0000000000001091. Epub ahead of print. PMID: 39813011.

Tags: Infectious Diseases, Publications

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Dao KT, D'Assumpcao C, Sharma R, Singh C, Kuran R, Heidari A. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Cureus. 2025 Feb 24;17(2):e79588.[...]

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes[...]

T cell immune senescence is associated with frailty and sarcopenia in lung transplant candidates

Schaenman JM, Pickering H, Reed EF, Rossetti M, Seligman B, Weigt SS, Shino M, Sayah D, Belperio J, Hu A, Prosper A, Ruchalski K, Ardehali[...]